Quest Partners LLC increased its holdings in Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Free Report) by 610.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 32,856 shares of the company’s stock after acquiring an additional 28,230 shares during the quarter. Quest Partners LLC owned approximately 0.11% of Aerovate Therapeutics worth $55,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of AVTE. Vanguard Group Inc. increased its stake in Aerovate Therapeutics by 7.2% in the first quarter. Vanguard Group Inc. now owns 672,275 shares of the company’s stock valued at $19,879,000 after purchasing an additional 45,444 shares during the period. Vestal Point Capital LP purchased a new position in shares of Aerovate Therapeutics during the fourth quarter worth about $9,052,000. Ikarian Capital LLC acquired a new position in Aerovate Therapeutics in the 1st quarter valued at about $10,881,000. SG Americas Securities LLC purchased a new stake in Aerovate Therapeutics during the 2nd quarter valued at approximately $298,000. Finally, Bank of New York Mellon Corp lifted its position in Aerovate Therapeutics by 69.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 46,988 shares of the company’s stock worth $78,000 after acquiring an additional 19,324 shares during the period.
Aerovate Therapeutics Stock Performance
Aerovate Therapeutics stock opened at $1.91 on Thursday. The company has a market cap of $55.05 million, a P/E ratio of -0.63 and a beta of 1.03. Aerovate Therapeutics, Inc. has a one year low of $1.25 and a one year high of $32.42. The business has a fifty day moving average of $1.84 and a two-hundred day moving average of $12.83.
Analyst Ratings Changes
A number of research analysts have recently issued reports on AVTE shares. Guggenheim reissued a “neutral” rating on shares of Aerovate Therapeutics in a report on Monday, June 17th. Wells Fargo & Company downgraded shares of Aerovate Therapeutics from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $35.00 to $2.00 in a research report on Tuesday, June 18th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $2.00 target price (down previously from $65.00) on shares of Aerovate Therapeutics in a report on Monday, June 17th. Evercore ISI lowered shares of Aerovate Therapeutics from an “outperform” rating to an “inline” rating and dropped their price target for the stock from $27.00 to $2.00 in a research note on Tuesday, June 18th. Finally, BTIG Research downgraded shares of Aerovate Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, June 17th. Six equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $2.25.
View Our Latest Research Report on Aerovate Therapeutics
About Aerovate Therapeutics
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Featured Articles
- Five stocks we like better than Aerovate Therapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- How Much Can You Make in Stocks in One Month?
- Top Stocks Investing in 5G Technology
- This Is the Top Large-Cap Stock Insiders Are Buying
- Most active stocks: Dollar volume vs share volume
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Want to see what other hedge funds are holding AVTE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Free Report).
Receive News & Ratings for Aerovate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerovate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.